In Vitro Nephrotoxicity Screening Using EGF Biomarker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to predictively assess the nephrotoxicity of nucleic acid-based drugs, such as siRNAs and antisense oligonucleotides, using in vitro cell-based assays, as existing biomarkers are ineffective for these drug classes.
Innovation Solution
An in vitro cell-based assay utilizing epidermal growth factor (EGF) as a biomarker, combined with adenosine triphosphate (ATP) and kidney injury molecule-1 (KIM-1), to predict in vivo nephrotoxicity by measuring EGF levels in the supernatant after drug substance administration to cells expressing EGFR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing biomarkers (KIM-1, ATP) are used in in vitro cell-based assays, then nephrotoxicity of small molecules can be predicted, but nephrotoxicity of nucleic acid-based drugs cannot be reliably predicted
Solution Approach 1:
The patent changes the biomarker parameter from existing markers (KIM-1, ATP) to EGF levels in cell culture supernatant. This parameter change enables reliable prediction of nephrotoxicity across different drug classes including nucleic acid-based drugs, resolving the contradiction between prediction reliability and drug class applicability
Solution Approach 2:
The patent creates a universal assay system using EGF as a biomarker that can predict nephrotoxicity for multiple drug classes (small molecules, peptides, nucleic acid-based drugs) simultaneously. This multi-functional approach eliminates the need for drug class-specific prediction methods
2Measurement precision
If in vivo toxicity screening is performed using animal models, then accurate nephrotoxicity assessment can be obtained, but animal usage increases and costs rise
Solution Approach 1:
The patent creates an in vitro copy model using human kidney cell lines (HEK293, HEK293T) that replicates in vivo nephrotoxicity responses. This cell-based copy system provides accurate toxicity assessment without requiring animal models, reducing animal usage while maintaining measurement precision
Solution Approach 2:
The patent introduces EGF levels in cell culture supernatant as an intermediary biomarker that mediates between in vitro drug exposure and in vivo nephrotoxicity outcomes. This intermediary enables accurate prediction without direct animal testing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for reliable prediction of nephrotoxicity, enabling the selection of non-toxic drug substances for in vivo administration, reducing animal usage and costs, and improving the therapeutic index of nucleic acid-based drugs.
Implementation Method 1
cells expressing epidermal growth factor receptor (EGFR)... measuring the levels of epidermal growth factor (EGF) as toxicity biomarker
Data Source
Figure 1~2
AI summary
The invention relates to methods for predicting the in vivo nephrotoxicity of a drug substance, in particular a nucleic acid molecule such as a siRNA or an antisense oligonucleotide using an in vitro cell based assay measuring the levels of extracellular EGF as toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1.